CWHM-12
Based on 10 publication(s) in Google Scholar
CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 1564286-55-0
- Formula: C26H32BrN5O6
- Molecular Weight:590.47
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-16141
CilengitideIntegrin Inhibitor -
HY-100506
GLPG0187Integrin Receptor Antagonist -
HY-15102
MK-0429αvβ3 Integrin Inhibitor -
HY-P0023
Cyclo(-RGDfK)αvβ3 Integrin Inhibitor -
HY-10431
SB-431542TGF-β Receptor Kinase Inhibitor -
HY-137561
Bexotegrastαvβ6/αvβ1 Integrin Inhibitor -
HY-19307
SB-273005αvβ3/αvβ5 Receptor Antagonist -
HY-16143
Cilengitide TFAIntegrin Inhibitor -
HY-14951
FirategrastIntegrin Antagonist -
HY-12041
SP600125JNK Inhibitor -
HY-100445A
αvβ1 integrin-IN-1 TFAαvβ1 Inhibitor -
HY-15770
TR-14035α4β7/α4β1 Antagonist
Publications Citing Use of MedChemExpress (MCE) CWHM-12
More- Cell. 2021 Sep 16;184(19):4919-4938.e22. [Abstract]
- Gastroenterology. 2026 Feb 27:S0016-5085(25)06526-6. [Abstract]
- Gut. 2022 Jan;71(1):55-67. [Abstract]
- Adv Fiber Mater. 2025 Dec 22.
- Adv Sci (Weinh). 2025 Oct 30:e01602. [Abstract]
- Cells. 2022 Jan 11;11(2):237. [Abstract]
- Glia. 2023 Feb;71(2):245-258. [Abstract]
- Sci Rep. 2021 Mar 15;11(1):5885. [Abstract]
- PLoS One. 2025 Jul 18;20(7):e0328263. [Abstract]
- bioRxiv. 2025 Sep 21.
Customer Validation & Images
-
WB
-
WB
-
Cell Imaging/Staining
-
WB
-
Others
Biological Activity
Description
IC50 & Target
IC50: 0.2 nM (αvβ8), 0.8 nM (αvβ3), 1.5 nM (αvβ6), 1.8 nM (αvβ1), 61 nM (αvβ5)[1]
In Vitro
CWHM-12 (CWHM 12) also less potently inhibits αvβ5 (IC50=61 nM) and αIIbβ3/α2β1/α10β1 (IC50>5000 nM). CWHM-12 demonstrates high potency against all of the five possible β subunit binding partners (αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8) in in vitro ligand-binding assays, with somewhat less potency against αvβ5 than against the other αv integrins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1564286-55-0
-
Appearance Solid
-
Molecular Weight 590.47
-
Formula C26H32BrN5O6
-
Color White to light brown
-
SMILES
O=C(CNC(C1=CC(NC2=NCC(O)CN2)=CC(O)=C1)=O)N[C@H](C3=CC(C(C)(C)C)=CC(Br)=C3)CC(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell
Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. [Abstract]2021 Sep 16;184(19):4919-4938.e22. PMID: 34506722
CWHM-12 purchased from MedChemExpress. Usage Cited in: Cell. 2021 Sep 16;184(19):4919-4938.e22. [Abstract]
In vitro transduction efficiency in human primary myotubes treated with different concentrations of CWHM-12 pan-integrin ɑV antagonists and transduced with AAV9- or MyoAAV 1A-CK8-Nluc.
-
Gastroenterology
Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy. [Abstract]2026 Feb 27:S0016-5085(25)06526-6. PMID: 41758081
CWHM-12 purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2026 Feb 27:S0016-5085(25)06526-6. [Abstract]
The p-FAK/FAK and YAP/p-YAP ratios were calculated. CTGF expression in HP-stimulated TMNK-1 cells treated with CWHM-12, verteporfin, a YAP inhibitor that disrupts YAP-TEA domain factor (TEAD) interactions, or YAP/TAZ short interfering RNA (siRNA).
CWHM-12 purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2026 Feb 27:S0016-5085(25)06526-6. [Abstract]
CWHM-12 (100 mg/kg/d). Western blot images of phosphorylated YAP (p-YAP) and YAP.
-
Gut
Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease. [Abstract]2022 Jan;71(1):55-67. PMID: 33468536 -
-
Adv Sci (Weinh)
Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface. [Abstract]2025 Oct 30:e01602. PMID: 41168993
CWHM-12 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 30:e01602. [Abstract]
Representative images from live cell microscopy phagocytosis assays of Protonex Red+ MDA‐MB‐231 cells treated with the integrin αv inhibitor CWHM‐12 (4 µM).
-
Cells
Wnt5A and TGFβ1 Converges through YAP1 Activity and Integrin Alpha v Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation. [Abstract]2022 Jan 11;11(2):237. PMID: 35053353
CWHM-12 purchased from MedChemExpress. Usage Cited in: Cells. 2022 Jan 11;11(2):237. [Abstract]
The Wnt5A overexpressing OVCAR-3 (C3/OVCAR-3) and SKOV-3 clones (C9/SKOV-3) were treated with CWHM-12 (10 μM) for 24 h.Immunoblot of TGFβ1, pSmad2/3, YAP1 determined in MCAs OvCa cells.
-
Glia
2023 Feb;71(2):245-258. PMID: 36106533 -
Sci Rep
Wnt5A modulates integrin expression in a receptor-dependent manner in ovarian cancer cells. [Abstract]2021 Mar 15;11(1):5885. PMID: 33723319 -
PLoS One
Odontogenesis-associated phosphoprotein (ODAPH) Promotes Ameloblast adhesion and alkaline phosphatase (ALP) expression via LAMC2/ ITGB6/TGF-β1 signaling pathway. [Abstract]2025 Jul 18;20(7):e0328263. PMID: 40680053 -
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (169.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24. [Content Brief]
[2]. Basta J, Robbins L, Stout L, Prinsen MJ, Griggs DW, Rauchman M. Pharmacologic inhibition of RGD-binding integrins ameliorates fibrosis and improves function following kidney injury. Physiol Rep. 2020;8(7):e14329. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6936 mL | 8.4678 mL | 16.9357 mL | 42.3392 mL |
| 5 mM | 0.3387 mL | 1.6936 mL | 3.3871 mL | 8.4678 mL | |
| 10 mM | 0.1694 mL | 0.8468 mL | 1.6936 mL | 4.2339 mL | |
| 15 mM | 0.1129 mL | 0.5645 mL | 1.1290 mL | 2.8226 mL | |
| 20 mM | 0.0847 mL | 0.4234 mL | 0.8468 mL | 2.1170 mL | |
| 25 mM | 0.0677 mL | 0.3387 mL | 0.6774 mL | 1.6936 mL | |
| 30 mM | 0.0565 mL | 0.2823 mL | 0.5645 mL | 1.4113 mL | |
| 40 mM | 0.0423 mL | 0.2117 mL | 0.4234 mL | 1.0585 mL | |
| 50 mM | 0.0339 mL | 0.1694 mL | 0.3387 mL | 0.8468 mL | |
| 60 mM | 0.0282 mL | 0.1411 mL | 0.2823 mL | 0.7057 mL | |
| 80 mM | 0.0212 mL | 0.1058 mL | 0.2117 mL | 0.5292 mL | |
| 100 mM | 0.0169 mL | 0.0847 mL | 0.1694 mL | 0.4234 mL |
CWHM-12 Related Classifications
HY-18644 Related Classifications
Powered by Bioz